torsemide 10 MG Oral Tablet
1 INDICATIONS AND USAGE Torsemide is a loop diuretic indicated for: the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Programβs Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. The antihypertensive effects of torsemide tablets are on the average greater in black patients than in nonblack patients [see Clinical Pharmacology (12.2) ]. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Torsemide tablets can be used alone or in combination with other antihypertensive agents.
aurobindo pharma limited
Related Pills
torsemide 20 MG Oral Tablet
aurobindo pharma limited
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING
TORSEMIDE Tablets USP 5 mg are white to off-white, oval shaped, biconvex, uncoated tablets debossed with βCβ on one side and with a score line in between β4β and β1β on the other side. Bottles of 100 NDC 65862-125-01 Bottles of 1,000 NDC 65862-125-99
TORSEMIDE Tablets USP 10 mg are white to off-white, oval shaped, biconvex, uncoated tablets debossed with βCβ on one side and with a score line in between β4β and β2β on the other side. Bottles of 100 NDC 65862-126-01 Bottles of 1,000 NDC 65862-126-99
TORSEMIDE Tablets USP 20 mg are white to off-white, oval shaped, biconvex, uncoated tablets debossed with βCβ on one side and with a score line in between β4β and β3β on the other side. Bottles of 100 NDC 65862-127-01 Bottles of 1,000 NDC 65862-127-99
TORSEMIDE Tablets USP 100 mg are white to off-white, capsule shaped beveled edge, uncoated tablets debossed with βCβ on one side and with a score line in between β4β and β4β on the other side. Bottles of 100 NDC 65862-128-01 Bottles of 1,000 NDC 65862-128-99 Store at 20Β° to 25Β°C (68Β° to 77Β°F); excursions permitted to 15Β° to 30Β°C (59Β° to 86Β°F) [see USP Controlled Room Temperature].
More pills like OVAL C 4 2